Compare International Business Machines Corp (IBM) vs Medpace Holdings Inc (MEDP) Price & Performance

IBM trades at $233.94, down 1.0% today, as the stock navigates mixed signals. Recent earnings showed a Q2 2026 EPS miss after two consecutive beats, while revenue growth accelerated to $67.54 billion in 2025. Technical indicators show a bullish overall signal but bearish moving averages, with RSI levels suggesting overbought conditions. The company secured a $240 million AI deal with Together AI, but faces securities fraud investigations following a 25% stock drop earlier this year.

IBM presents a complex risk-reward profile with strong profitability metrics (15.52% net margin, 34.62% ROE) and analyst consensus pointing to 10% upside to the $257.38 price target. However, ongoing legal investigations and increased capital expenditures creating negative cash flow pose significant near-term risks. The AI partnership momentum contrasts with concerns about IBM's competitive positioning in the rapidly evolving technology landscape.

MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.

Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.